Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03484767 · ClinicalTrials.gov registry record
"The MaP Study": Mapping the Patient Journey in MMA and PA
A clinical trial of Methylmalonic Acidemia and Propionic Acidemia, sponsored by ModernaTX.
- Completed
- Registry status
- 97
- Enrollment target
- 17
- Study locations
NCT03484767: Completed study of Methylmalonic Acidemia and Propionic Acidemia, sponsored by ModernaTX.
NCT03484767 is a study of Methylmalonic Acidemia and Propionic Acidemia that has completed, run by ModernaTX. The registered enrollment target is 97 participants, below the 411-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (76% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03484767, a study of Methylmalonic Acidemia and Propionic Acidemia, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
- 17
- Study locations
Study Summary
Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA to characterize the changes in blood disease biomarkers over time and the frequency and severity of clinical events related to their disease.
Conditions Studied
Study Locations (17)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- University of Pittsburgh - Pittsburgh
Other
- Birmingham Children's Hospital - Birmingham
- Manchester University Hospitals - Manchester
California
- Stanford Health Services - Stanford
Georgia
- Emory Univeristy - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Massachusetts
- Boston Children's Hospital - Boston
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2021-05-29 |
What the finished NCT03484767 record still lists
NCT03484767 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 411-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Methylmalonic Acidemia appearing as the primary indexed condition, and to 0 interventions.
NCT03484767 lists 17 locations in 15 states (Pennsylvania, Other, California).
Frequently Asked Questions
What is clinical trial NCT03484767 about?
NCT03484767 is a clinical study titled ""The MaP Study": Mapping the Patient Journey in MMA and PA". Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA to characterize the changes in blood disease biomarkers over time and the frequency and severity of clinical events related to their disease.
What is the current status of trial NCT03484767?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2018-03-20. Estimated completion is 2021-05-29.
What conditions does trial NCT03484767 study?
This clinical trial studies the following conditions: Methylmalonic Acidemia, Propionic Acidemia.
Who is sponsoring clinical trial NCT03484767?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03484767 being conducted?
This trial has 17 study locations across California, Georgia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methylmalonic Acidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
RECRUITING · Phase 1
-
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
RECRUITING
-
Clinical and Laboratory Study of Methylmalonic Acidemia
RECRUITING
-
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
ACTIVE NOT RECRUITING · Phase 1
-
Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
ACTIVE NOT RECRUITING
-
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI